COFCO Biotechnology Salute del bilancio

Salute finanziaria criteri di controllo 5/6

COFCO Biotechnology ha un patrimonio netto totale di CN¥10.9B e un debito totale di CN¥3.9B, che porta il suo rapporto debito/patrimonio netto a 35.4%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥17.2B e CN¥6.3B.

Informazioni chiave

35.4%

Rapporto debito/patrimonio netto

CN¥3.86b

Debito

Indice di copertura degli interessi	n/a
Contanti	CN¥1.67b
Patrimonio netto	CN¥10.90b
Totale passività	CN¥6.28b
Totale attività	CN¥17.18b

Aggiornamenti recenti sulla salute finanziaria

We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt

Sep 30

COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt

Jun 03

Recent updates

COFCO Biotechnology Co., Ltd. (SZSE:000930) Surges 39% Yet Its Low P/S Is No Reason For Excitement

Oct 14

We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt

Sep 30

COFCO Biotechnology Co., Ltd. (SZSE:000930) Looks Inexpensive But Perhaps Not Attractive Enough

Jul 17

COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt

Jun 03

Returns On Capital Signal Tricky Times Ahead For COFCO Biotechnology (SZSE:000930)

Apr 17

COFCO Biotechnology Co., Ltd.'s (SZSE:000930) Price Is Right But Growth Is Lacking

Mar 07

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥6.8B ) di 000930 superano le sue passività a breve termine ( CN¥5.7B ).

Passività a lungo termine: Le attività a breve termine di 000930 ( CN¥6.8B ) superano le sue passività a lungo termine ( CN¥618.2M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 20.1% ) di 000930 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 000930 si è ridotto da 49.6% a 35.4% negli ultimi 5 anni.

Copertura del debito: Il debito di 000930 è ben coperto dal flusso di cassa operativo ( 20.5% ).

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di 000930 siano ben coperti dall'EBIT.

COFCO Biotechnology Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt

COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt

Recent updates

Third quarter 2024 earnings released: CN¥0.028 loss per share (vs CN¥0.001 profit in 3Q 2023)

COFCO Biotechnology Co., Ltd. (SZSE:000930) Surges 39% Yet Its Low P/S Is No Reason For Excitement

COFCO Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt

COFCO Biotechnology Co., Ltd. Announces Board Changes

Second quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.18 loss in 2Q 2023)

COFCO Biotechnology Co., Ltd. (SZSE:000930) Looks Inexpensive But Perhaps Not Attractive Enough

COFCO Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

High number of new and inexperienced directors

COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt

First quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.001 in 1Q 2023)

COFCO Biotechnology Co., Ltd., Annual General Meeting, May 16, 2024

Returns On Capital Signal Tricky Times Ahead For COFCO Biotechnology (SZSE:000930)

COFCO Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

COFCO Biotechnology Co., Ltd.'s (SZSE:000930) Price Is Right But Growth Is Lacking

COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.097 in 3Q 2022)

COFCO Biotechnology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.23 profit in 2Q 2022)

COFCO Biotechnology Co., Ltd. Implements Cash Dividend (A shares) for 2022, Payable on July 03, 2023

COFCO Biotechnology Co., Ltd. Approves the Election of Wang Laichun as a Non-Employee Supervisor

Full year 2022 earnings released: EPS: CN¥0.57 (vs CN¥0.61 in FY 2021)

Price target increased to CN¥13.68

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.097 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.19 in 2Q 2021)

COFCO Biotechnology Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 10 June 2022

COFCO Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2021

COFCO Biotechnology Co., Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CN¥13.68

High number of new and inexperienced directors

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.091 in 3Q 2020)

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.14 in 2Q 2020)

Cofco Biotechnology Co., Ltd. Approves Final Cash Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥0.32 (vs CN¥0.32 in FY 2019)

Investor sentiment deteriorated over the past week

New 90-day high: CN¥10.11

Investor sentiment improved over the past week

New 90-day high: CN¥9.64

Third quarter earnings released

COFCO Biotechnology Co., Ltd. to Report Q3, 2020 Results on Oct 26, 2020

First half earnings released

New 90-day high - CN¥11.13

COFCO Biotechnology Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥8.19

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane